Literature DB >> 28839937

Proteomic and transcriptomic analyses to explain the pleiotropic effects of Ankaferd blood stopper.

Cem Simsek1, Sebnem Selek2, Meltem Koca1, Ibrahim Celal Haznedaroglu3.   

Abstract

Ankaferd blood stopper is a standardized mixture of the plants Thymus vulgaris, Glycyrrhiza glabra, Vitis vinifera, Alpinia officinarum, and Urtica dioica and has been used as a topical hemostatic agent and with its clinical application established in randomized controlled trials and case reports. Ankaferd has been successfully used in gastrointestinal endobronchial mucosal and cutaneous bleedings and also in abdominal, thoracic, dental and oropharyngeal, and pelvic surgeries. Ankaferd's hemostatic action is thought to form a protein complex with coagulation factors that facilitate adhesion of blood components. Besides its hemostatic action, Ankaferd has demonstrated pleiotropic effects, including anti-neoplastic and anti-microbial activities and tissue-healing properties; the underlying mechanisms for these have not been well studied. Ankaferd's individual components were determined by proteomic and chemical analyses. Ankaferd also augments transcription of some transcription factors which is shown with transcriptomic analysis. The independent effects of these ingredients and augmented transcription factors are not known precisely. Here, we review what is known of Ankaferd blood stopper components from chemical, proteomic, and transcriptomic analyses and propose that individual components can explain some pleiotropic effects of Ankaferd. Certainly more research is needed focusing on individual ingredients of Ankaferd to elucidate their precise and effects.

Entities:  

Keywords:  Ankaferd blood stopper; genomic analysis; hemostasis; pleiotropic effect; proteomic analysis

Year:  2017        PMID: 28839937      PMCID: PMC5536373          DOI: 10.1177/2050312117722569

Source DB:  PubMed          Journal:  SAGE Open Med        ISSN: 2050-3121


Ankaferd Blood Stopper is a standardized mixture of plants Thymus vulgaris, Glycyrrhiza glabra, Vitis vinifera, Alpinia offacinarum and Urticora dioica plants and have been used as a topical hemostatic agent. As a traditional medicine, Ankaferd is shown to have pleiotropic effects. ABS demonstrated anti-neoplastic, anti-microbial actions, also promoted tissue healing. In this study, literature about ingredients of ABS formula with respect to previously performed chemical, transcriptomic and genomic analysis is presented to explain these pleiotropic effects.

Introduction and effects of Ankaferd

Ankaferd is a novel hemostatic agent that was formulated from a traditional extract used in Anatolia and is a standardized mixture of the plants Thymus vulgaris, Glycyrrhiza glabra, Vitis vinifera, Alpinia officinarum, and Urtica dioica. Ankaferd’s hemostatic action and clinical application has been established in randomized controlled trials and case reports. However, Ankaferd has pleiotropic effects including anti-neoplastic, anti-microbial, anti-mutagenic, and antioxidant as well as tissue-healing properties,[1] although the underlying mechanisms have not been well studied. Here, we review the literature on Ankaferd to clarify the mechanistic basis of this pleiotropism. The procoagulant function of Ankaferd blood stopper (ABS) has been extensively discussed elsewhere.[2] Ankaferd has been successfully used as a topical hemostatic agent, for example, in the treatment of digestive tract ulcers as well as various types of bleeding including variceal/non-variceal, gastrointestinal,[3-5] endobronchial,[6] mucosal (including in patients with hemorrhagic diathesis[7-9]), and cutaneous.[10] Ankaferd has also been employed in abdominal, thoracic, dental and oropharyngeal, and pelvic surgeries (Table 1).[11-14] The precise mechanism of Ankaferd’s hemostatic action is not known, but it is thought to form a protein complex with intrinsic coagulation factors that facilitate erythrocyte and thrombocyte adhesion. The hemostatic mechanism of Ankaferd will not be further addressed here; instead, we refer readers to a recent review of this subject.[2]
Table 1.

Clinical trials on Ankareferd’s hemostatic action.

AuthorYearNumber of populationStudy designDiagnosis of patientsClinical settingsConclusionsPerspectives
Yaman et al.[15]201230RandomizedCarious primary molar teeth of 6–9 years old childrenABS was compared with formocresol for 3, 6, and 12 months for pain, swelling, mobility, resorption, furcation, and periapical bone destructionABS was as effective as formocresol as a pulp dressing of primary molarABS appears to be an alternative pulpectomy agent
Iynen et al.[16]201190Prospective<18-year-old patients who needed adenoidectomyThe study assessed the clinical effect of ABS on hemostasis in adenoidectomy and post-adenoidectomy patientsABS reduces the duration and blood loss of an adenoidectomy and increases postoperative quality of lifeIn situations when pinpointing the source of the hemorrhage in the nasopharynx is difficult, tampons soaked in ABS are extremely useful in stopping the hemorrhage
Teker et al.[17]200949Prospective, randomized, controlled, non-blinded, clinical trialPatients with anterior epistaxisThe efficacy of ABS as a hemostatic agent compared to hemostasis by phenylephrine was observedABS is effective, safe, quick, and easy alternative to the phenylephrine in patients with anterior epistaxisABS is an effective agent to control bleeding in cases that could not be managed by vasoconstrictor agents
Uzun et al. [6]201320Retrospective studyPatients with hemoptysis who needed bronchoscopic proceduresThe study was done to evaluate the hemostatic efficacy of endobronchial application of ABS solution in patients with hemoptysisBleeding could be controlled with ABS a few seconds after instillation in the hemorrhagic focus in 23 interventions, but it was ineffective in 2 cases.Bronchoscopic application of ABS may be an alternative supportive treatment in cases of uncontrolled hemoptysis.
Guler et al.[18]201161Prospective, randomized, controlled trialPatients with benign euthyroid multinodular goiter who needed total thyroidectomyThe study was designed prospectively to compare ABS and HCT groups in terms of operation time, postoperative drainage, duration of postoperative stay, and complicationsThe use of ABS is more effective than HCT to control hemorrhage following total thyroidectomyThe usage of ABS might be more effective in preventing hematoma by stopping oozing-type bleeding without causing an increase in hemostasis-related complications
Pamuk et al.[20]201515Prospective, randomized clinical studyPatients with chronic periodontitisFollowing the initial periodontal therapy, patients were randomly assigned to two treatments in contralateral areas of the dentition: ACB + ABS or ACB alone and the procedures were appliedABS enhances the soft tissue healing during the periodontal defect fill by the ACB by stimulating angiogenesis and vascular endothelial cell function, prevents GR and thereby increases the clinical attachment gainThe results indicate that (1) both treatment modalities resulted in statistically significant clinical improvements compared with baseline, (2) ABS may improve the regenerative process and cause less GR, and (3) ABS may lead to an increase in levels of the VEGF in the healing stage of periodontal surgery
Istanbulluoglu et al.[21]201390Prospective, randomized clinical studyPatients who undergone PCNL because of renal and/or upper ureter stones45 of the patients underwent tubeless PCNL with the use of ABS as a hemostatic agent, whereas the remaining ones underwent tubeless PCNL without ABS and the procedures were appliedABS is an efficient and reliable hemostatic agent in tubeless PCNLABS is a safe and reliable method in tubeless or totally tubeless PCNL interventions leading to expectations that these procedures might find widespread use among endourologists
Amer et al.[22]2013205Prospective, randomized clinical studyPatients with a single tooth to be extracted that can be removed with forceps without the need for mucoperiosteal flap and/or dental elevators were included in this studyPatients were selected so that 80 patients have INR values of ≤2, whereas the remaining patients have the INR values ranging from 2 to 3 and the procedures were appliedABS is an effective hemostatic agent comparable to tranexamic acid in controlling post-extraction bleeding in AOT patients of INR values ≤3 with no evidence support the superiority of tranexamic acid over ABSFor patients with INR values >2 ABS can represent itself as a sufficient local hemostatic agent that is comparable with tranexamic acid
Atalay et al.[23]201550Randomized, prospective clinical studyCABG patients who medicated with clopidogrel and ASA prior to CABG surgery25 CABG patients received a high-dose clopidogrel (600 mg) and 300 mg ASA have been included into the study (ABC group). 25 patients have also been included into the study for comparison and the procedures were appliedLocal use of ABC decrease the bleeding from the mediastinum after CABGABC seems to be effective agent to inhibit blood loss after CABG without any complication and provides a significant reduction of bleeding in patients medicated with high-dose clopidogrel
Yasar et al.[24]200960Prospective, non-randomized, non-blinded observational studyPatients who were subjected to the intended procedure if having an upper airway obstruction due to adenoid tissueEach child was assigned either to the ABS or the SS group in order of appearance on the surgical waiting listA statistically significantly shorter duration of bleeding and a statistically lower number of packs are required to achieve ABS tamponade-induced hemostasis during adenoidectomy as compared to saline soaked gauze sponge applicationABS aids in the control of intraoperative bleeding and reduces the number of packs required to achieve hemostasis, so that it can be recommended for tamponades performed during pediatric adenoidectomies
Teker et al.[17]200947Prospective, non-randomized, non-blinded studyPatients with chronic tonsillitis, tonsillar hypertrophy, and obstructive sleep apnea syndromePatients with bleeding disorders, aspirin use within 2 weeks prior to surgery, peritonsillar abscess history, acute tonsillitis within 4 weeks prior to surgery, tonsillectomy due to malignity suspicion, and children with systemic diseases were excluded and the procedures were appliedABS reduces intraoperative hemorrhage and operation timeIt is a safe, efficient, and easy to use hemostatic agent with no side effects and it is recommended to use ABS during routine tonsillectomy for healthy children
Akpinar et al.[19]201550Double-blind, placebo-controlled, randomized clinical trialPatients with unstable angina unsuitable for percutaneous coronary intervention who were scheduled for urgent or acute CABGTwenty-five emergency CABG patients premedicated with clopidogrel and ASA were included in the study (Group 1). An additional 25 patients who were premedicated with the same antiplatelet agents were selected as a control group (Group 2)The use of local ABS reduces bleeding, transfusion requirements of packed red blood cells, platelets, and total blood units in patients premedicated with clopidogrel and ASA undergoing emergent CABGThis study demonstrated that a significant reduction in bleeding and requirement for transfusion can be achieved with the use of ABS in emergency CABG patients premedicated with a high dose of clopidogrel
Eyi Yapar et al. [25]201240Prospective, randomized clinical studyPregnant women with a term singleton fetus in a vertex position who required a mediolateral episiotomyThe patients were randomly assigned to two approaches (20 to ABS, 20 to SS)Application of 4 mL of ABS instead of SS lessened bleedingThe study revealed a positive effect of the topical application of ABS tested for bleeding reduction
Atay et al.[9]201320Prospective, randomized clinical studyPatients with oral mucositis of grade 3–4 according to the WHO classificationAfter patients developed oral mucositis they used only ABS, and age and gender of patients, type of the underlying malignant disease and used chemotherapeutic drugs, frequency, amount and duration of ABS use and healing time of oral mucositis were recordedThe healing duration of oral mucositis was shorter with the topical ABS application. And also the hemorrhages from oral mucositis lesions were recovered within 2 days with ABSABS is an effective agent in the chemotherapy-related severe oral mucositis treatment of the patients with hematological malignancies. ABS shortens the healing time with acceptable side effects
[26] 200823Clinical trialDental treatments with bleeding such as periodontitis, tooth removal, etc.Use of ABS in dental procedures was observed both by physical examination and laboratory testsLaboratory findings were not affected by ABS application. No GIS side effects were observedABS is safe for oral-topical use

ACB: autogenous cortical bone greft, ABS: Ankaferd blood stopper; AOT: Oral anticoagulant therapy; CABG: coronary artery bypass grafting; ASA: acetylsalicylic acid; INR: international normalized ratio; GIS: gastrointestinal system; GR: gingival recession; HCT : hemostasis by conventional technique; PCNL: percutaneous nephrolithotomy; SS: saline solution; VEGF: vascular endothelial growth factor.

Clinical trials on Ankareferd’s hemostatic action. ACB: autogenous cortical bone greft, ABS: Ankaferd blood stopper; AOT: Oral anticoagulant therapy; CABG: coronary artery bypass grafting; ASA: acetylsalicylic acid; INR: international normalized ratio; GIS: gastrointestinal system; GR: gingival recession; HCT : hemostasis by conventional technique; PCNL: percutaneous nephrolithotomy; SS: saline solution; VEGF: vascular endothelial growth factor. Ankaferd has long been known to promote the repair of bone, periodontal, muscle, skin, gastrointestinal, and oropharyngeal tissues and urogenital mucosae after surgery or injury, although some contradictory findings have been reported.[27-30] The antimicrobial activity of Ankaferd is thought to derive from its oxygen-enhancing capacity through erythrocyte aggregation. The antimicrobial spectrum is broad and includes microorganisms such as methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa, Klebsiella, Acinetobacter baumannii, Mycobacterium tuberculosis, and Candida albicans.[31,32] Ankaferd has also been used to treat hydatid cysts via injection.[33,34] Less is known about the anti-neoplastic activity of Ankaferd, although it was shown to inhibit cell proliferation, promote apoptosis, and prevent blast cell transformation of B-cell chronic lymphocytic leukemia cells in vitro.[35] It has also demonstrated toxicity toward multiple myeloma and plasmacytoma cells both in vitro and in vivo, while decreasing M protein production.[36,37] Other solid malignancies such as sarcoma and colon cancer are also targets of the anti-neoplastic action of Ankaferd.

Method

The constituents of Ankaferd have been identified by proteomic and transcriptomic analyses.[38,39] Proteins were searched in the Uniprot Protein Knowledge Database by accession number, whereas genes were searched in the GeneCards database. Both proteins and genes were searched in National Library for Health and Institute for Scientific Information databases. References and related literature were reviewed by three authors. Based on this information, we hypothesized that the constituents of Ankaferd contribute to each of its three major pleiotropic actions, which are discussed below.

Antimicrobial effects

Ankaferd has antibacterial, germicidal, and antimycobacterial effects. In vitro studies have shown that ABS is effective against both Gram-positive and Gram-negative bacteria;[40] foodborne pathogens such as Escherichia coli and Salmonella typhimurium;[41] resistant nosocomial pathogens such as Pseudomonas, Klebsiella, Acinetobacter, Enterococcus, and Staphylococcus species;[42] Echinococcus granulosus;[33] and resistant Tuberculosis strains. The antimicrobial effects of Ankaferd may be attributable to its chemical components. A time-of-flight mass spectroscopy analysis of ABS revealed the presence of the antioxidants tocotrienol, tryptophan, thymol, lycophene, enoxolone, tomatine, tertiary butylhydroquinone, vitamin E derivatives, and galangin.[43]

Anti-neoplastic effects

Another property of Ankaferd is the capacity to inhibit neoplasia. ABS has demonstrated cytotoxicity against human erythrocytes at some concentrations, as well as against tumoral cells in hematologic malignancies such as multiple myeloma, chronic myelogenous leukemia, and lymphoma.[35,37,44] Possible related ingredients of Ankaferd are CREBZF, PIAS-2, HNF-4a, ME-1, P18INK4C, and Midkine and addressed below in alphabetical order. In transcriptome analyses, ABS has been found to increase the expression of cyclic AMP response element-binding protein (CREB)/ATF BZIP transcription factor (CREBZF), a member of the mammalian CREB family of transcription factors; this increased the level of the anti-neoplastic protein p53, thereby enhancing gene transcription.[45] CREBZF also regulates the unfolded protein response to protect against excessive protein synthesis during endoplasmic reticulum stress.[46] Hepatocyte nuclear factor (HNF)-4a is a nuclear receptor found not only in the liver but also in other tissues, which is involved in embryonic development, cellular differentiation, and hepatocyte-specific protein synthesis. Recent studies have shown that HNF-4a also has anti-neoplastic activity, with its inhibition leading to tumor growth.[47] HNF-4a is a component of ABS extract and may be partly responsible for its anti-tumorigenic effects. Malic enzyme (ME)-1 is an intracellular cytosolic protein and a component of ABS that converts malic acid to pyruvic acid, yielding nicotinamide adenine dinucleotide phosphate (NAPDH). ME-1 plays an important role in cancer metabolism, since NADPH is required for anaerobic respiration; indeed, ME-1 level is upregulated in some cancers.[48,49] However, the role of ME-1 in ABS remains unclear given that it remains outside of cells, and its in vivo function has not been investigated. Midkine is a heparin-binding protein that is involved in cellular growth, survival, migration, and differentiation. Midkine was found to suppress vascular endothelial growth factor A, which plays a key role in tumoral angiogenesis; its inhibition may thus inhibit tumor growth.[50,51] Although a more likely role for midkine is the promotion of tissue healing (discussed below), we speculate that it also has anti-tumoral effects. Protein inhibitor of activated signal transducer and activator of transcription (PIAS)-2 is another component of ABS extract. This protein belongs to PIAS family, whose members suppress the activity of STAT proteins,[52] which are critical components of the Janus kinase (JAK) cascade that acts downstream of many growth factor receptors. JAK-STAT signaling is a major pathway involved in human carcinogenesis.[53] Thus, the anti-neoplastic action of ABS may be exerted via inhibition of STAT protein via PIAS-2. The cyclin-dependent kinase (CDK) inhibitor P18INK4C[54] inhibits tumorigenesis, and its deficiency promotes tumor growth.[55,56] CDKs are serine/threonine kinases that regulate the cell cycle and thus play a vital role in human cancers. P18INK4C may participate in the tumor-suppressor activity of ABS by inhibiting CDKs.

Tissue-healing effects

In addition to being a hemostatic agent, ABS has an established role in promoting tissue repair after radiation damage and colitis;[57] bone, cartilage, muscle, and tendon remodeling;[27,58,59] and repair of dermal and epidermal tissue,[29] gastrointestinal mucosa, and full-thickness injuries in the abdominal viscera.[9,60] We hypothesize that Dynactin, Egr-1, Midkine, NF-1, Twinfilin, V-myc, and Yin Yang 1 can contribute to this effect thus mentioned in following paragraphs with possible mechanisms. Dynactin along with its partner motor protein dynein is an integral component of cytoskeletal machinery that controls organelle movement during cell division. Dynactin has a central alpha helix with adjacent peptides that interact with dynein and other proteins. Dynactin is an ABS constituent; given its filamentous structure and capacity for integrating with other structures in vivo, it may contribute to the stimulatory effect of ABS on tissue healing.[61,62] Inflammation is an integral aspect of tissue repair. Early growth factor (Egr)-1 is a transcription factor and ubiquitous growth factor present in ABS that has an important role in cell proliferation and differentiation. Increasing Egf-1 transcriptional activity may promote tissue regeneration.[63,64] Midkine, the heparin-binding protein described above, is known to stimulate the growth of and provide protection to tissue,[65] but also regulates immunity and inflammation. Midkine promotes endothelial cell proliferation and angiogenesis and has been implicated in the pathogenesis of various diseases.[66] Neurofibromin (NF)-1 is a tumor suppressor whose mutation is linked to neurofibromatosis type 1 and juvenile myelomonocytic leukemia. It is a Ras GTPase-activating protein that inhibits Ras and regulates the growth and differentiation of keratinocytes; it is overexpressed in the human epidermis during tissue repair.[67,68] Twinfilin is an actin monomer-binding protein that stabilizes and facilitates the function of actin fibrils.[69] It is highly conserved between yeasts, humans, and other mammals. Twinfilin in ABS may interact with extracellular actin to form a protein scaffold that facilitates tissue repair.[70] V-myc avian myelocytomatosis viral oncogene homolog (c-myc) and its product nuclear c-Myc phosphoprotein play a key role in cell cycle progression and cell growth and transformation. Although c-myc is a known oncogenic protein, its transcription is upregulated during wound healing;[71] as such, it may be another ABS component that contributes to tissue repair. Yin Yang 1 is a ubiquitous and highly conserved transcription factor enriched in ABS that is known to promote cell differentiation, proliferation, and growth, especially in the central nervous system, and protect against apoptosis.[72]

Conclusion

The aim of this review is to constitute a framework for future research about pleiotropic effects of ABS. It is composed of hypotheses of Ankaferd ingredients’ individual contributions to pleiotropic effects. There are some limitations of this review. The hypotheses are constructed regarding the molecules’ actions in literature. First, these effects may not be reproduced in vivo and within the environment that the drug acts. Discrete studies on each ingredient is needed to confirm isolated effects of these molecules. Second, there may be some alternative explanations for these effects including contribution of other molecules or divergent effects of known molecules. Third, the process for each pleiotropic action needs to be explained more precisely with more studies to enable better assumptions and a more straightforward research tract about underlying molecular processes. Ankaferd is an effective hemostatic agent that has been shown to be effective in suppressing gastrointestinal, dental, urologic, oropharyngeal, thoracic, and dermal bleeding in clinical trials. Animal studies and case reports have demonstrated the pleiotropic effects of Ankaferd that may have therapeutic benefits, although there have been no controlled clinical trials evaluating this in humans. We hypothesized that specific factors in ABS contribute to this pleiotropism (Table 2). Additional studies investigating these individual components can broaden the therapeutic potential and applicability of ABS.
Table 2.

Hypothesized mechanisms of individual components’ contributions on Ankaferd’s pleiotropic effects.

Pleiotropic effectComponentRelevance
Anti-neoplastic effectsCREBZFIncreases p53 transcription
PIAS2Inhibits activity of STAT proteins
HNF-4aIts inhibition promotes tumor growth
ME-1It converts malic acid to pyruvic acid resulting in production of NADPH
P18INK4CInhibits CDKs
MidkineDownregulates VEGF-A
Tissue-healing effectsDynactinHas a filamentous structure and potential to integrate with other structures in vivo
Egr-1Has an important role in cell proliferation and differentiation
MidkinePromotes endothelial cellular proliferation and angiogenesis
C-mycPlays a key role in progression of cell cycle, cellular growth, cellular transformation
NF-1Inhibits RAS and regulates growth and differentiation of keratinocytes and its increased expression is shown in healing tissues in human epidermis
TwinfilinInteracts with extracellular actin to promote protein scaffold for tissue healing
YY1Promotes cellular differentiation, proliferation, and growth, also is shown to protect from apoptosis
Antimicrobial effectsTocotrienols vitamin E familyHave distinct antioxidant effects
GalanginThe topoisomerase IV enzyme may therefore be implicated in the antibacterial mechanism of action of galangin
ApigeninHas an antioxidant, anticarcinogenic, and spasmolytic activities and can reduce high blood pressure
Tertiary butylhydroquinone (TBHQ)Prompts loss of staphylococcal membrane integrity
BHT (butylated hydroxytoluene)Has an antioxidant effect
Hypothesized mechanisms of individual components’ contributions on Ankaferd’s pleiotropic effects.
  63 in total

1.  Role of early growth response-1 (Egr-1) in interleukin-13-induced inflammation and remodeling.

Authors:  Soo Jung Cho; Min Jong Kang; Robert J Homer; Hye Ryun Kang; Xuchen Zhang; Patty J Lee; Jack A Elias; Chun Geun Lee
Journal:  J Biol Chem       Date:  2006-01-26       Impact factor: 5.157

2.  Antimicrobial activity of plant extract Ankaferd Blood Stopper.

Authors:  Nuriye Tasdelen Fisgin; Yeliz Tanriverdi Cayci; Ahmet Yilmaz Coban; Duzgun Ozatli; Esra Tanyel; Belma Durupinar; Necla Tulek
Journal:  Fitoterapia       Date:  2008-10-07       Impact factor: 2.882

3.  The effect of Ankaferd blood stopper on severe radiation colitis.

Authors:  E Ozaslan; T Purnak; A Yildiz; T Akar; U Avcioglu; I C Haznedaroglu
Journal:  Endoscopy       Date:  2009-11-17       Impact factor: 10.093

4.  Functional role of Egr-1 mediating VEGF-induced tissue factor expression in the retinal capillary endothelium.

Authors:  Yukio Sassa; Yasuaki Hata; Toshinori Murata; Ichiro Yamanaka; Masae Honda; Toshio Hisatomi; Kimihiko Fujisawa; Taiji Sakamoto; Toshiaki Kubota; Kazunori Nakagawa; Katsuo Sueishi; Tatsuro Ishibashi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2002-11-06       Impact factor: 3.117

5.  Ankaferd blood stopper decreases postoperative bleeding and number of transfusions in patients treated with clopidogrel: a double-blind, placebo-controlled, randomized clinical trial.

Authors:  Mehmet Besir Akpinar; Atakan Atalay; Hakan Atalay; Omer Faruk Dogan
Journal:  Heart Surg Forum       Date:  2015-06-26       Impact factor: 0.676

6.  Effects of Ankaferd on anastomotic healing of colon.

Authors:  Gulden Cancan; Serkan Teksoz; Erman Aytac; Akif Enes Arikan; Hayriye Erman; Hafize Uzun; Ferhat Ozden; Ovgu Aydin; Murat Ozcan
Journal:  J Invest Surg       Date:  2013-08-29       Impact factor: 2.533

7.  The effects of Ankaferd® Blood Stopper on transcription factors in HUVEC and the erythrocyte protein profile.

Authors:  Erkan Yılmaz; Şükrü Güleç; Didem Torun; İbrahim Celalettin Haznedaroğlu; Nejat Akar
Journal:  Turk J Haematol       Date:  2011-12-05       Impact factor: 1.831

8.  Beneficial effects of Ankaferd Blood Stopper on dermal wound healing: an experimental study.

Authors:  Cagri Akalin; Serdar Kuru; Aziz Mutlu Barlas; Kemal Kismet; Bugra Kaptanoglu; Aydin Demir; Hesna Muzeyyen Astarci; Huseyin Ustun; Ertugrul Ertas
Journal:  Int Wound J       Date:  2012-09-03       Impact factor: 3.315

9.  Zhangfei/CREB-ZF - a potential regulator of the unfolded protein response.

Authors:  Rui Zhang; Noreen Rapin; Zhengxin Ying; Erika Shklanka; Timothy W Bodnarchuk; Valerie M K Verge; Vikram Misra
Journal:  PLoS One       Date:  2013-10-14       Impact factor: 3.240

10.  Anti-inflammatory efficiency of Ankaferd blood stopper in experimental distal colitis model.

Authors:  Erdem Koçak; Erdem Akbal; Adnan Taş; Seyfettin Köklü; Gökhan Karaca; Murat Can; Bahadir Kösem; Hüseyin Üstün
Journal:  Saudi J Gastroenterol       Date:  2013 May-Jun       Impact factor: 2.485

View more
  2 in total

1.  The efficacy of Ankaferd Blood Stopper® in an experimental Asherman syndrome model created in rats.

Authors:  Başak Büyük; Fatma Beyazıt
Journal:  Turk J Obstet Gynecol       Date:  2019-03-27

Review 2.  A review of the effects of Urtica dioica (nettle) in metabolic syndrome.

Authors:  Bahareh Samakar; Soghra Mehri; Hossein Hosseinzadeh
Journal:  Iran J Basic Med Sci       Date:  2022-05       Impact factor: 2.532

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.